NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
China Pharma Holdings, Inc. CPHI
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.1M
▼ 8.5% vs FY2024
EPS · FY25
$-0.74
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-20.9%
Net margin · FY25
-76.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.1M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 77 cents on every revenue dollar this year.
Per share
USD -0.74
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-20.9%
Return on equity, FY2025
ROE
Operating margin-78.2%
Net margin-76.9%
Return on assets-13.9%
Each USD of equity lost 21 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−17.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−20.0%
−17.5%
−14.7%
−17.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+4.6%
Change, 10 years+5.0%
The share count grew 5% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 31.0M
total assets, end of FY2025
Total assetsUSD 31.0M
EquityUSD 22.7M
CashUSD 345,112.00
Gross debtUSD 1.4M
Net debtUSD 1.1M
Current ratio0.32×
Net debt stands at 5% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.1
0.1
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
Income tax $B
·
·
·
·
·
·
·
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
EPS, diluted $
−0.74
−2.71
−0.91
−3.78
−0.74
−0.07
−0.48
−0.25
−0.44
−0.21
−0.35
−0.91
−0.46
0.11
0.44
0.54
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−20.9
−62.3
−52.4
−77.1
−48.5
−33.3
−105.0
−29.3
−37.8
−14.0
−18.6
−35.0
−14.2
3.2
14.8
19.9
Shares out B
0.02
0.00
0.01
0.00
0.00
0.05
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
58 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 4 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed